Finance

Lists
Why is VTVT down 4,02%?
Dive Deeper
VTVT:NASDAQ
vTv Therapeutics Inc
USD 30,57
-4,02%
(-1,28) 1D
USD 31,20
+2,06% (+0,63)
After hours
Closed: 2 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTVT...
Open
USD 32,20
High
USD 32,32
Low
USD 30,57
Mkt. cap
120,87 m
Avg. vol.
46,94 k
Volume
18,02 k
52-wk high
USD 44,00
52-wk low
USD 19,80
EPS
-USD 1,06
Beta
0,23
Shares outstanding
3,95 m
No. of employees
26
Open
USD 32,20
High
USD 32,32
Low
USD 30,57
Mkt. cap
120,87 m
Avg. vol.
46,94 k
Volume
18,02 k
52-wk high
USD 44,00
52-wk low
USD 19,80
EPS
-USD 1,06
Beta
0,23
Shares outstanding
3,95 m
No. of employees
26
News stories
From web sources and news partners
About vTv Therapeutics Inc
CEO-
Employees26
Founded2015
HeadquartersHigh Point, Noord-Carolina, Verenigde State van Amerika
Sector-
Websitevtvtherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to VTVT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for VTVT in the last 3 months.
Highest
Current USD 30,57
USD 67,00 (+119,17%)
Average
USD 56,80 (+85,80%)
Lowest
USD 42,00 (+37,39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Emily Bodnar
H.C. Wainwright
Buy
Maintained
USD 42,00
+37,4%
09/21/2026
Patrick Dolezal
LifeSci Capital
Buy
Initiated
USD 60,00
+96,3%
09/02/2026
Adam Walsh
Roth MKM
Buy
Reiterated
USD 58,00
+89,7%
08/07/2026
Kambiz Yazdi
BTIG
Buy
Maintained
USD 57,00
+86,5%
08/06/2026
Ritu Baral
TD Cowen
Buy
Maintained
USD 67,00
+119,2%
08/07/2026
Michael King
Rodman & Renshaw
Buy
Initiated
USD 67,00
+119,2%
06/30/2026
James Molloy
Alliance Global Partners
Buy
Reiterated
USD 55,00
+79,9%
05/14/2026
Michael DiFiore
Evercore ISI
Buy
Initiated
USD 44,00
+43,9%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
36,84 m
-
Cost of goods sold
7,02 m
3,91 m
8,98 m
8,77 m
Cost of revenue
7,02 m
3,91 m
8,98 m
8,77 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,68 m
3,98 m
4,60 m
5,16 m
Operating expense
3,68 m
3,98 m
4,60 m
5,16 m
Total operating expenses
10,70 m
7,88 m
13,58 m
13,93 m
Operating income
-10,70 m
-7,88 m
23,26 m
-13,93 m
Other non operating income
-40,00 k
-117,00 k
33,00 k
64,00 k
EBT including unusual items
-10,34 m
-7,14 m
24,13 m
-13,05 m
EBT excluding unusual items
-10,34 m
-7,14 m
24,13 m
-13,05 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8,70 m
-7,14 m
24,13 m
-13,05 m
Net profit margin
-
-
65,51%
-
Earnings per share
-1,08
-0,58
1,65
-1,05
Interest and investment income
399,00 k
865,00 k
838,00 k
812,00 k
Interest expense
-5,00 k
-1,00 k
-
-
Net interest expenses
394,00 k
864,00 k
838,00 k
812,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,70 m
-7,88 m
23,26 m
-13,93 m
Gain or loss from assets sale
-
6,00 k
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme